The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis
Abstract
Background Ursodeoxycholic acid probably is not able to cure primary biliary cirrhosis. Therefore in this study ursodeoxycholic acid was administered together with prednisolone, since monotherapy with glucocorticoids has been shown to have some positive effects. Methods Thirty patients with primary biliary cirrhosis (stages I-III) were entered into the study. Fifteen were treated with ursodeoxycholic acid 10 mg.kg-1.day-1 and placebo (group A), 15 with ursodeoxycholic acid and 10 mg prednisolone (group B) for 9 months. Apart from the usual laboratory examinations, liver biopsies were taken from 29 patients before and after therapy. Results Liver enzymes decreased significantly compared to the initial values in both groups (p < 0.001), but in group B cholestasis-indicating enzymes and the immunoglobulins G and A improved more rapidly. Between both groups the differences for AP, GGT, IgG, IgA and gamma-globulins were significant (p < 0.05), but only for short terms. In group B, liver histology improved significantly (p < 0.003), which correlated with the decrease of IgG. Ursodeoxycholic acid became the predominant bile acid in the serum. Toxic bile acids did not increase. Bone densitometry revealed a slight deterioration of preexisting osteoporosis in one patient. Conclusions Although combination therapy with ursodeoxycholic acid and prednisolone was not superior to monotherapy with ursodeoxycholic acid with regard to liver function tests, it had a highly beneficial influence on liver histology. In our previous trials with monotherapy histology remained unchanged. An early decrease in IgG during combination therapy seems to be an indicator of an amelioration of liver histology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 1994 and 1996, two studies evaluated the administration of ursodeoxycholic acid (UDCA), a hydrophilic secondary bile acid, in patients with cystic fibrosis–associated liver disease (200) and early-stage primary biliary cirrhosis (201), respectively, reporting modest improvements in liver function.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [201]
Citations
Cites
PRACTICAL STEREOLOGICAL METHODS FOR MORPHOMETRIC CYTOLOGY
Weibel, E. R., Kistler, G., & Scherle, W. F. (1966) · The Journal of Cell Biology · doi:10.1083/jcb.30.1.23 · Cited by 1,838
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Ursodeoxycholic acid in primary biliary cirrhosis: Results of a controlled double-blind trial
Leuschner, U., Fischer, H., Kurtz, W., Güldütuna, S., Hübner, K., Hellstern, A., Gatzen, M., & Leuschner, M. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)91698-3 · Cited by 352
Self-citationCOMBES, B., Carithers, R. L., Maddrey, W. C., Lin, D., McDonald, M. F., Wheeler, D. E., Eigenbrodt, E. H., Muñoz, S. J., Rubin, R., Garcia-Tsao, G., et al. (1995) · Hepatology · doi:10.1016/0270-9139(95)90294-5 · Cited by 303
A controlled trial of prednisolone treatment in primary biliary cirrhosis
Mitchison, H. C., Palmer, J. M., Bassendine, M. F., Watson, A. J., Record, C. O., & James, O. (1992) · Journal of Hepatology · doi:10.1016/0168-8278(92)90065-w · Cited by 199
Mitchison, H. C., Bassendine, M. F., Malcolm, A. J., Watson, A. J., Record, C. O., & James, O. (1989) · Hepatology · doi:10.1002/hep.1840100405 · Cited by 151
Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy
Poupon, R. E., Chrétien, Y., Poupon, R. Y., & Paumgartner, G. (1993) · Hepatology · doi:10.1002/hep.1840170412 · Cited by 119
Stiehl, A., Rudolph, G., Raedsch, R., Möller, B., Hopf, U., Lotterer, E., Bircher, J., Fölsch, U. R., Klaus, J., Endele, R., et al. (1990) · Hepatology · doi:10.1002/hep.1840120308 · Cited by 115
Research works printed but not linked: 3
- David, 1985, Die Wirkung von Ursodesoxycholsäure bei chronischen Leberkrankheiten, Eine Pilotstudie (abstr.). Z Gastroenterol, 23, 420
- Schaffner, 1991, Ursodeoxycholic acid (U) + colchicine (C) for treatment of primary biliary cirrhosis (PBC) (abstr.), Hepatology, 14, 62A
- Kaplan, 1992, The therapeutic effects of ursodiol and methotrexate are additive and well tolerated in primary biliary cirrhosis (abstr.), Hepatology, 16, 92A
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Corpechot, C., Chazouillères, O., & Poupon, R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.02.031 · Cited by 460
Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’
Lazaridis, K. N., Gores, G. J., & Lindor, K. D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00092-7 · Cited by 428
Metadata
- Authors
- Leuschner, M., Güldütuna, S., You, T., Hübner, K., Bhatti, S., & Leuschner, U.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Leuschner, Ulrich
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 1996-07
- Volume
- 25
- Issue
- 1
- Pages
- 49-57
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2012146760
- Cited by
- 119
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 3 · 2015: 5 · 2014: 6 · 2013: 1 · 2012: 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary biliary cirrhosis, ursodeoxycholic acid, prednisolone, combination therapy, glucocorticoids, liver histopathology, IgG, cholestasis, serum bile acids, osteoporosis, early-stage disease
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunoglobulin G, Liver, Liver Cirrhosis, Biliary, Male, Middle Aged, Prednisolone, Prospective Studies, Ursodeoxycholic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
